Working… Menu

A Phase I/II Study With BM7PE Immunotoxin in Colorectal Cancer Patients (BM7PE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04550897
Recruitment Status : Recruiting
First Posted : September 16, 2020
Last Update Posted : February 17, 2021
Information provided by (Responsible Party):
Geir Olav Hjortland, Oslo University Hospital

Brief Summary:
This phase 1/2 study will evaluate the safety, tolerance and dose of BM7PE treating patients with colorectal cancer who have progressed to standard cell therapy or cannot tolerate such therapy. The study starts as a phase 1 study with the aim of assessing the final dose for this group of patients. Based on the results, the study will continue into a phase 2. The phase 2 study aim to examine overall survival ≥ 9.3 months.

Condition or disease Intervention/treatment Phase
Colorectal Cancer Metastatic Drug: BM7PE Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Phase 1 study in colorectal cancer patients
Masking: None (Open Label)
Primary Purpose: Other
Official Title: A Phase 1/2 Study With BM7PE Immunotoxin in Colorectal Cancer Patients With Metastatic Disease Who Are Refractory to or With Intolerance to Last Line of Standard Chemotherapy.
Actual Study Start Date : August 31, 2020
Estimated Primary Completion Date : December 31, 2022
Estimated Study Completion Date : December 31, 2022

Arm Intervention/treatment
Experimental: BM7PE treatment

The BM7PE treatment will be administered as a 20-minute i.v. infusion. The treatment is repeated after 2 weeks (day 15). The patients will be treated as in-patients and will stay at the hospital until toxicity have decreased to grade 2 and or plasma AST and or ALT levels has started to decrease. For at least a minimum of 3 days.

The dose administered to the patient will be 2.5, 5.0, 7.5, 10.0, 15.0 and 20.0 μg/kg body weight.

Drug: BM7PE
BM7PE immunotoxin is supplied as a liquid solution and is diluted in 0.9% saline to a total volume of 250 ml.

Primary Outcome Measures :
  1. Adverse Events related to BM7PE [ Time Frame: 30 days after last dose of BM7PE ]
    To characterize the safety and toxicity of BM7PE by register adverse event in accordance with CTCAE 5.0

Secondary Outcome Measures :
  1. Efficacy of the BM7PE: Overall survival [ Time Frame: Through study completion, an average of 1 year ]
    The Overall survival will be measured by death registration

  2. Efficacy of the BM7PE: progression free survival [ Time Frame: From date of first treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months ]
    The progression free survival will be measured by MR (RECIST 1.1)

  3. Radiological response to BM7PE [ Time Frame: From date of first treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months ]
    Will be measured by CT (RECIST 1.1) response rate

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically verified adenocarcinoma of colon or rectum
  • Ambulatory with an ECOG performance status 0-1
  • At least 18 years of age
  • Progressive disease on or last line of standard chemotherapy or intolerance to further chemotherapy
  • Laboratory values as the following: ANC, Platelets, Hb, Creatinine, Bilirubin, ASAT, ALAT, Albumin levels, INR
  • Signed informed consent and expected cooperation of the patients for the treatment, and follow-up must be obtained and documented according to ICH GCP, and national/local regulations

Exclusion Criteria:

  • History of prior metastatic disease the last 3 years
  • History of CNS or bone metastases
  • Significant cardiac or other medical illness that would limit activity or survival, such as severe congestive heart failure, unstable angina, or serious cardiac arrhythmia
  • Chemotherapy/radiation therapy or major surgery within the last 4 weeks before start of treatment
  • Alcohol or drug abuse
  • Any reason why, in the opinion of the investigator, the patient should not participate
  • Has a known history of Human Immunodeficiency Virus (HIV)
  • Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected)
  • Is pregnant or breastfeeding, or expecting to conceive or father children within the project duration of the trial, starting with the screening visit through 120 days after the last dose of trial treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04550897

Layout table for location contacts
Contact: Geir O Hjortland, MD PhD 22934000

Layout table for location information
Oslo University Hospital Recruiting
Oslo, Norway, 0310
Contact: Geir O Hjortland, MD PhD    22934000 ext 47   
Sponsors and Collaborators
Oslo University Hospital
Layout table for investigator information
Principal Investigator: Geir O Hjortland, MDPhD Oslo University Hospital
Layout table for additonal information
Responsible Party: Geir Olav Hjortland, Principal Investigator, Oslo University Hospital Identifier: NCT04550897    
Other Study ID Numbers: BM7PE
First Posted: September 16, 2020    Key Record Dates
Last Update Posted: February 17, 2021
Last Verified: February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Geir Olav Hjortland, Oslo University Hospital:
Intolerance last line standard chemotherapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases